Remicade Safety Line (Ankylosing Spondylitis)(Study P03275)(COMPLETED)

Merck Sharp & Dohme (MSD)

Status: Completed

Conditions: Spondylitis, Ankylosing

Treatments: Biological: Infliximab

Study type: Observational

Funder types: Industry

Identifiers

NCT00818168

P03275

Details and patient eligibility

About

This observational study is in line with the German educational plan with the aim to implement a tool to increase and monitor the awareness of tuberculosis screening and to reinforce the patient eligibility for a treatment with Remicade according to the Summary of Product Characteristics (SmPc).

Full description

This study population was chosen from a non-probability sample.

Enrollment: 320 patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects with ankylosing spondylitis.

Exclusion criteria

• As per Summary of Product Characteristics (SmPC)

Trial design

320 participants in 1 patient group

Infliximab

Description:

Subjects with ankylosing spondylitis who were treated with infliximab. The dosage and infusion intervals were employed in accordance to the Summary of Product Characteristics (SmPC)

Treatment:

Biological: Infliximab